DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract Eckert & Ziegler to become the long-term contrast agent supplier to leading Polish clinic chain - new production location in Warsaw being planned 02.03.2011 / 11:18 --------------------------------------------------------------------- Berlin, 2 March 2011. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in the production of radioactive contrast agents for cancer detection, has concluded a long-term contract with Euromedic International B.V., based in Budapest, to supply Polish diagnostics centres. The framework agreement for so-called FDG (Fluorodeoxyglucose (18 F)) also envisages the creation of a pharmaceutical production facility in Warsaw in addition to the FDG supply. Eckert & Ziegler radiopharmacy Director, Dr. André Heà and Axel Schmidt, Managing Director of the group subsidiary Eckert & Ziegler f-con Deutschland GmbH that manages the project, declared in a joint statement: 'Euromedic is a strategic partner with whom we have already been successfully cooperating for many years. We support the further expansion of the Polish cancer treatment centres with the creation of a new radiodiagnostics production plant near Warsaw and are looking forward to closer cooperation with Euromedic. It enables us to further expand our industry leadership in Germany to Eastern Europe.' FDG will be used within the framework of positron emission tomography (PET) for the safe and early detection of even the smallest tumor foci. As a result of its short half-life, FDG has to be produced daily on locally cited cyclotrons and delivered to the clinics as soon as possible. Eckert & Ziegler currently supplies a host of Polish PET-CT centres from its production facility in Berlin. Eckert & Ziegler has several radiopharmaceutical production locations in Germany and in addition to Fluor-18 based radiodiagnostics for nuclear medical imaging (PET), also markets the licensed product Yttriga, a precursor agent used in radiolabeling for the production of numerous radiotherapeutics. Eckert & Ziegler additionally supplies nuclear medical facilities with synthesis technology and Gallium-68 (PET) radionuclide generators worldwide. About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG is an isotope technology company which operates worldwide and is the holding company for a host of specialised subsidiaries engaged in the processing of radioisotopes as well as the development, production and the sales of isotope technical components, medical technical devices and related products. The group of companies has 550 employees worldwide and is among the largest providers of radioactive components for radiation therapy and nuclear medicine. You can find further information about Eckert & Ziegler under www.ezag.de. About Euromedic: Euromedic is one of the largest and most successful providers of medical services in Europe. The company specialises in diagnostic examinations, dialysis and teleradiology and has more than 6000 employees in 207 medical centres. After almost two decades in the service of high-quality medical care, Euromedic has re-defined the relationship between privately financed health care and the public sector. The company provides life-saving medical services, within the existing, publicly managed health care system. The company has been engaged in Poland since 2000 where it operates 19 dialysis centres as well as 18 diagnostics centres, among these are three PET-CT locations in Wroclaw, Warsaw and Poznan. You can find further information about Euromedic under www.euromedic.com. Your contact in case you have any further questions: Eckert & Ziegler AG, Karolin Riehle, Public Relations Robert-Rössle-Str. 10, D-13125 Berlin Tel.: +49 (0) 30 / 941084-138, Fax-112 E-Mail: karolin.riehle@ezag.de, www.ezag.de End of Corporate News --------------------------------------------------------------------- 02.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Deutschland Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, Düsseldorf, Hamburg, München End of News DGAP News-Service --------------------------------------------------------------------- 114138 02.03.2011
DGAP-News: Eckert & Ziegler to become the long-term contrast agent supplier to leading Polish clinic chain - new production location in Warsaw being planned
| Source: EQS Group AG